Alto Neuroscience Completes Enrollment In ALTO-100 Phase 2b Study, Topline Results Expected In October
Portfolio Pulse from Benzinga Newsdesk
Alto Neuroscience has completed enrollment for its ALTO-100 Phase 2b study, with 300 patients participating. The company is on track to report topline results in October 2024 and will host an investor day on September 9, 2024, focused on ALTO-100.
July 16, 2024 | 11:36 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Alto Neuroscience has completed enrollment for its ALTO-100 Phase 2b study, with results expected in October 2024. An investor day is scheduled for September 9, 2024.
The completion of enrollment for the ALTO-100 Phase 2b study is a significant milestone for Alto Neuroscience. The upcoming topline results and investor day could generate positive investor sentiment and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100